LifeStance Health Group (NASDAQ:LFST) Sees Unusually-High Trading Volume on Analyst Upgrade

LifeStance Health Group, Inc. (NASDAQ:LFST) saw strong trading volume on Thursday after Canaccord Genuity Group raised their price target on the stock from $9.00 to $10.00. Canaccord Genuity Group currently has a buy rating on the stock. 2,944,276 shares were traded during mid-day trading, an increase of 64% from the previous session’s volume of 1,795,452 shares.The stock last traded at $7.0950 and had previously closed at $7.41.

Other analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. KeyCorp raised their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday. BTIG Research lifted their target price on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Finally, UBS Group boosted their target price on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Moderate Buy” and an average target price of $9.67.

Insiders Place Their Bets

In other LifeStance Health Group news, insider Ann Varanakis sold 50,000 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the transaction, the insider directly owned 315,610 shares of the company’s stock, valued at $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the sale, the director owned 1,318,983 shares in the company, valued at approximately $9,285,640.32. This trade represents a 8.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 270,086 shares of company stock worth $1,891,264 in the last three months. 3.20% of the stock is owned by corporate insiders.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Company posted strong Q4 and full‑year results: Q4 revenue +17% to $382.2M, adjusted EBITDA and net income turned positive, and management guided 2026 revenue of $1.615B–$1.655B with higher EBITDA targets — bolstering growth expectations. Read More.
• Positive Sentiment: Board approved a $100M share repurchase program (up to ~3.6% of shares), signaling management confidence and potential support for the stock. Read More.
• Positive Sentiment: Multiple brokers raised price targets and ratings (UBS to $12 buy; Canaccord to $10 buy; KeyCorp to $9 overweight), reflecting improved sell‑side sentiment and providing upside anchors. Read More.
• Neutral Sentiment: Earnings were mixed: revenue and visits/clinician growth beat expectations, but GAAP EPS came in at $0.03 versus consensus ~$0.05 — the miss tempers the positive top‑line story. Read More.
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares; LifeStance is not selling and receives no proceeds — the large potential supply increase likely pressured the share price despite company fundamentals. Read More.
• Negative Sentiment: High trading volume and reported insider/institutional selling (recent insider sales and large institutional position changes) amplify near‑term downside risk as the market absorbs both the EPS miss and the offering. Read More.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors have recently bought and sold shares of LFST. Vanguard Group Inc. raised its holdings in shares of LifeStance Health Group by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after acquiring an additional 3,086,506 shares during the last quarter. Silversmith Partners I GP LLC purchased a new stake in shares of LifeStance Health Group during the fourth quarter worth approximately $100,842,000. Dimensional Fund Advisors LP increased its position in shares of LifeStance Health Group by 6.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 8,906,465 shares of the company’s stock worth $62,704,000 after purchasing an additional 542,858 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in LifeStance Health Group by 27.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock valued at $43,071,000 after purchasing an additional 1,324,691 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Stock Down 6.1%

The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $7.12 and a two-hundred day simple moving average of $6.18. The company has a market cap of $2.71 billion, a PE ratio of 348.17 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The business had revenue of $382.20 million during the quarter, compared to analyst estimates of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.66%. LifeStance Health Group’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.01) earnings per share. As a group, equities research analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

LifeStance Health Group announced that its board has approved a share buyback plan on Wednesday, February 25th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to buy up to 3.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.